18F-FMISO PET评估放射性栓塞治疗前肿瘤缺氧状态:ARTE-MISO试验
这项单中心前瞻性研究纳入25例原发性或转移性肝肿瘤患者,在TARE前用18F-FMISO PET/CT评估缺氧,治疗后用18F-FDG PET评估疗效。结果显示平均吸收剂量和缺氧状态均为治疗反应的显著预测因素,非缺氧/高剂量病灶反应率最高(93%),缺氧/低剂量最低(39%)。
要点
- 高平均吸收剂量(>89 Gy)病灶反应率86%,低剂量病灶为56%。
- 缺氧病灶(T/BP>1.29)反应率57%,非缺氧病灶(T/BP<1.29)反应率91%。
- 非缺氧/高剂量病灶反应率最高(93%),缺氧/低剂量病灶最低(39%)。
核心结论
- 本研究发现平均吸收辐射剂量和缺氧状态均为肝肿瘤放射性栓塞治疗后反应的显著预测因素。
- 作者指出需要更大规模研究来确认这些发现,本先导研究可能为通过进一步个体化治疗改善放射性栓塞疗效铺平道路。
研究设计与样本
- 单中心前瞻性研究,纳入25例原发性或转移性肝肿瘤患者,TARE前接受18F-FMISO PET/CT显像,并接受90Y树脂微球治疗。
- 治疗后用18F-FDG PET评估反应,通过计算肿瘤/肌肉(T/M)和肿瘤/血池(T/BP)比值评估缺氧状态,吸收剂量指标来自术后90Y PET/MRI。
主要发现
- 共评估54个18F-FDG高摄取病灶;患者平均年龄60.4±12岁,56%为男性。
- 中位平均吸收剂量(Dmean):完全缓解(CR)为114.8 Gy,部分缓解(PR)为98.9 Gy,疾病稳定(SD)为56.7 Gy,疾病进展(PD)为78.3 Gy。
- 缓解组与非缓解组之间Dmean(P=0.013)和T/BP比值(P=0.011)差异有统计学意义。
- 高Dmean病灶(>89 Gy)反应率为86%,低Dmean病灶为56%;缺氧病灶(T/BP>1.29)反应率为57%,非缺氧病灶(T/BP<1.29)为91%。
- 联合分析中,非缺氧/高Dmean病灶反应率最高(93%),缺氧/低剂量病灶反应率最低(39%)。
关键数值与推荐
- 病灶按反应分类为完全缓解(CR)、部分缓解(PR)、疾病稳定(SD)和疾病进展(PD)。
- 缺氧状态以T/BP>1.29定义为缺氧,T/BP<1.29为非缺氧;高Dmean定义为>89 Gy。
- 统计分析包括ROC曲线分析、χ2检验和回归模型以确定治疗反应的预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需要更大规模研究来确认这些发现。
- 原文称本研究为先导研究(pilot study)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transarterial radioembolization (TARE) is a therapeutic option for patients with liver tumors. However, factors responsible for treatment resistance in TARE remain largely unknown. In this study, we aimed to investigate the role of hypoxia in the treatment response of liver tumors using 18 F-FMISO PET imaging before TARE. PATIENTS AND METHODS: This single-center prospective study included 25 patients with primary or metastatic liver tumors imaged with 18 F-FMISO PET/CT before TARE and treated with 90 Y resin microspheres. Posttreatment response was assessed with 18 F-FDG PET imaging. Hypoxia status was evaluated by calculating the tumor-to-muscle (T/M) and tumor-to-blood pool (T/BP) ratios. Absorbed dose metrics were derived from 90 Y PET/MRI imaging post-procedure. Lesions were categorized by response as complete responders (CR), partial responders (PR), stable disease (SD), and progressive disease (PD). Statistical analyses included ROC curve analysis, χ2 tests, and regression models to determine predictors of treatment response. RESULTS: Among 25 patients (mean age: 60.4 ± 12 y, 56% males), 54 18 F-FDG-avid lesions were evaluated. The median absorbed dose (Dmean) was 114.8 Gy for CR, 98.9 Gy for PR, 56.7 Gy for SD, and 78.3 Gy for PD. Significant differences in Dmean ( P = 0.013) and T/BP ratios ( P = 0.011) were observed between responder and nonresponder groups. High Dmean lesions (>89 Gy) had a response rate of 86%, compared with 56% in low Dmean lesions. Hypoxic lesions (T/BP >1.29) showed a 57% response rate, while non-hypoxic lesions (T/BP <1.29) showed a 91% response rate. In combined analyses, while non-hypoxic/high Dmean lesions had the highest response rates (93%), hypoxic/low-dose had the lowest response rate (39%). CONCLUSIONS: In this study, we have observed that both mean absorbed radiation dose and hypoxia status are significant predictors of response to treatment after radioembolization of liver tumors. While larger studies are needed to confirm these findings, this pilot study may pave the way for further personalized treatments to achieve better results for radioembolization.
引用
- Soydal C, Demir B, Celebioglu EC, et al. Assessment of Hypoxia Before Radioembolization Treatment With 18 F-FMISO PET : ARTE-MISO Trial. Clin Nucl Med. 2025. PMID: 40296277. doi:10.1097/RLU.0000000000005918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。